Inhibrx Biosciences, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-193.3M | $-197.9M | $4.6M | $24.8M |
| FY2024 | $-194.4M | $-197.0M | $2.6M | $58.5M |
| FY2025 | $-129.8M | $-129.8M | $31.0K | $11.1M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-193.3M | $-197.9M | $4.6M | $24.8M |
| FY2024 | $-194.4M | $-197.0M | $2.6M | $58.5M |
| FY2025 | $-129.8M | $-129.8M | $31.0K | $11.1M |